

Richard I Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11124566/publications.pdf>

Version: 2024-02-01

175
papers

46,402
citations

10389

72
h-index

4432

172
g-index

180
all docs

180
docs citations

180
times ranked

25818
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	1.6	4,061
2	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. <i>Journal of Clinical Oncology</i> , 2014, 32, 3059-3067.	1.6	3,729
3	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	27.0	3,474
4	Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 1999, 17, 1244-1244.	1.6	3,209
5	Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1993, 328, 1002-1006.	27.0	2,035
6	A Prognostic Score for Advanced Hodgkin's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1506-1514.	27.0	1,553
7	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	1.4	1,552
8	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	27.8	1,402
9	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	27.0	1,293
10	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	27.8	1,292
11	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	1.6	1,269
12	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3121-3127.	1.6	1,203
13	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	8.5	1,002
14	Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1998, 339, 21-26.	27.0	929
15	Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients. <i>New England Journal of Medicine</i> , 1990, 323, 1723-1728.	27.0	883
16	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	7.1	868
17	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	16.8	848
18	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	27.0	824

#	ARTICLE	IF	CITATIONS
19	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. <i>Science</i> , 2008, 319, 1676-1679.	12.6	784
20	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	27.8	759
21	Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4867-4874.	1.6	675
22	Overview of non-Hodgkin's lymphoma: Biology, staging, and treatment. <i>Seminars in Oncology</i> , 2003, 30, 3-9.	2.2	512
23	Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin's Disease: Report of an Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 607-614.	1.6	438
24	New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 8447-8452.	1.6	368
25	Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP Chemotherapy. <i>Annals of Internal Medicine</i> , 1983, 98, 304.	3.9	354
26	The epidemiology of non-Hodgkin's lymphoma. <i>Oncogene</i> , 2004, 23, 6524-6534.	5.9	349
27	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	1.4	348
28	Diffuse Large B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 941-952.	2.2	340
29	Advanced Ovarian Adenocarcinoma. <i>New England Journal of Medicine</i> , 1978, 299, 1261-1266.	27.0	326
30	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1681-1690.	27.0	298
31	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	1.4	296
32	Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4302-4311.	1.6	285
33	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	1.6	266
34	Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911. <i>Journal of Clinical Oncology</i> , 2006, 24, 4143-4149.	1.6	260
35	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	1.6	256
36	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006, 107, 4207-4213.	1.4	248

#	ARTICLE	IF	CITATIONS
37	Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. <i>Journal of Clinical Oncology</i> , 2008, 26, 2258-2263.	1.6	247
38	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	1.6	239
39	Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 7565-7573.	1.6	226
40	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	1.4	226
41	Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516. The Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 114-119.	1.6	226
42	Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. <i>American Journal of Medicine</i> , 1977, 63, 177-182.	1.5	212
43	Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse. <i>Annals of Internal Medicine</i> , 1979, 90, 761.	3.9	207
44	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012, 120, 3280-3287.	1.4	188
45	The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 2807-2812.	1.4	186
46	Central nervous system complications of non-Hodgkin's lymphoma. <i>American Journal of Medicine</i> , 1979, 66, 435-443.	1.5	181
47	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007, 204, 633-643.	8.5	176
48	Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	1.6	176
49	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. <i>Clinical Immunology</i> , 2007, 122, 139-145.	3.2	167
50	A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. <i>Blood</i> , 2003, 102, 1606-1612.	1.4	165
51	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	1.6	152
52	Non-Hodgkin's Lymphomas, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1282-1303.	4.9	144
53	Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin's Disease. <i>Journal of Clinical Oncology</i> , 2001, 19, 4238-4244.	1.6	143
54	Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. <i>Blood</i> , 2009, 113, 3809-3812.	1.4	141

#	ARTICLE	IF	CITATIONS
55	Persistent Immunologic Abnormalities in Long-Term Survivors of Advanced Hodgkin's Disease. <i>Annals of Internal Medicine</i> , 1980, 92, 595.	3.9	123
56	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	1.4	117
57	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <i>tanford V</i> in older <i>H</i> odgkin lymphoma patients: a comprehensive analysis from the <i>N</i> orth <i>A</i> merican intergroup trial <i>E</i> 2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	2.5	111
58	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	4.9	107
59	Diffuse histiocytic lymphoma involving the gastrointestinal tract. <i>Cancer</i> , 1978, 41, 1984-1989.	4.1	106
60	The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. <i>Blood</i> , 2010, 115, 4478-4487.	1.4	105
61	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
62	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 20-47.e30.	2.0	91
63	Health Status and Quality of Life in Patients With Early-Stage Hodgkin's Disease Treated on Southwest Oncology Group Study 9133. <i>Journal of Clinical Oncology</i> , 2003, 21, 3512-3519.	1.6	90
64	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 356-364.e3.	0.4	88
65	Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-PI). <i>British Journal of Haematology</i> , 2010, 151, 143-151.	2.5	85
66	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. <i>Leukemia and Lymphoma</i> , 2009, 50, 728-735.	1.3	84
67	The Bruton tyrosine kinase (<i>BTK</i>) inhibitor <i>PCI-32765</i> synergistically increases proteasome inhibitor activity in diffuse large B cell lymphoma (<i>DLBCL</i>) and mantle cell lymphoma (<i>MCL</i>) cells sensitive or resistant to bortezomib. <i>British Journal of Haematology</i> , 2013, 161, 43-56.	2.5	81
68	Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial. <i>Surgical Clinics of North America</i> , 1981, 61, 1267-1277.	1.5	76
69	Diffuse Large B-Cell Lymphoma Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 196-231.	4.9	76
70	A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. <i>British Journal of Haematology</i> , 2009, 145, 741-748.	2.5	75
71	Phase II study of a TLR9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 282-291.	2.5	75
72	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75

#	ARTICLE	IF	CITATIONS
73	Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin's Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809. <i>Journal of Clinical Oncology</i> , 2000, 18, 2010-2016.	1.6	74
74	Diffuse Aggressive Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 221-236.	2.5	74
75	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 371-379.	4.1	74
76	Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349). <i>Journal of Clinical Oncology</i> , 2003, 21, 2466-2473.	1.6	71
77	Leukemic transformation in polycythemia vera: Analysis of risk factors. <i>American Journal of Hematology</i> , 1990, 34, 32-36.	4.1	70
78	Peritoneoscopy in the management of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1981, 140, 611-619.	1.3	69
79	Simian Virus 40 Is Present in Most United States Human Mesotheliomas, but It Is Rarely Present in Non-Hodgkin's Lymphoma. <i>Chest</i> , 1999, 116, 470S-473S.	0.8	69
80	A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. <i>Leukemia and Lymphoma</i> , 2012, 53, 259-262.	1.3	69
81	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	1.4	68
82	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹ I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	1.6	68
83	Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. <i>Haematologica</i> , 2012, 97, 937-942.	3.5	64
84	Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1686-1697.	4.1	60
85	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. <i>Journal of Clinical Oncology</i> , 2015, 33, 1482-1490.	1.6	60
86	Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. <i>Journal of Immunotherapy</i> , 1994, 15, 147-153.	2.4	58
87	A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. <i>Blood</i> , 2012, 120, 1210-1217.	1.4	58
88	The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 529-539.	2.0	55
89	Evaluation of the International Prognostic Score (IPS ⁷) and a Simpler Prognostic Score (IPS ³) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	2.5	54
90	Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. <i>Cancer</i> , 1978, 42, 2157-2161.	4.1	53

#	ARTICLE	IF	CITATIONS
91	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 308-331.	2.0	52
92	Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 2210-2219.	7.0	51
93	Natural history of malignant lymphomas with divergent histologies at staging evaluation. <i>Cancer</i> , 1981, 47, 2022-2025.	4.1	49
94	Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501. <i>Journal of Clinical Oncology</i> , 2003, 21, 1996-2003.	1.6	48
95	Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. <i>British Journal of Haematology</i> , 2016, 172, 208-218.	2.5	45
96	Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1876-1884.	1.6	43
97	BCL-2 Expression Correlates With Lower Proliferative Activity in the Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study. <i>Blood</i> , 1998, 91, 1391-1398.	1.4	41
98	FOLLICULAR LYMPHOMAS:. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 893-900.	2.2	40
99	R-CHOP but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	2.5	40
100	Non-Hodgkin's Lymphomas, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 916-946.	4.9	38
101	A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. <i>American Journal of Hematology</i> , 2018, 93, 486-493.	4.1	38
102	Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy-Resistant Non-Hodgkin Lymphoma. <i>American Journal of Hematology</i> , 1978, 5, 203-209.	4.1	37
103	Multiple recurrences of acute tumor lysis syndrome in an indolent non-hodgkin's lymphoma. <i>Cancer</i> , 1985, 56, 2295-2297.	4.1	37
104	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 135-141.	0.4	37
105	Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2. <i>PLoS ONE</i> , 2014, 9, e95184.	2.5	35
106	BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. <i>Cancer Biology and Therapy</i> , 2009, 8, 808-819.	3.4	34
107	Involved Field Radiation After Autologous Stem Cell Transplant for Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 79-85.	0.8	34
108	Advances in the staging and treatment of ovarian cancer. <i>Cancer</i> , 1977, 39, 967-972.	4.1	33

#	ARTICLE	IF	CITATIONS
109	<sc>R</sc>â€œ<sc>CHOP</sc> with iodineâ€œ131 tositumomab consolidation for advanced stage diffuse large <sc>B</sc>â€œcell lymphoma (<sc>DLBCL</sc>): <sc>SWOG S</sc>0433. British Journal of Haematology, 2014, 166, 382-389.	2.5	33
110	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology, 2015, 33, 1936-1942.	1.6	33
111	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leukemia and Lymphoma, 2016, 57, 2359-2369.	1.3	33
112	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOPâ€œRituximab versus CHOP + 131Iodineâ€œTositumomab. Clinical Cancer Research, 2013, 19, 6624-6632.	7.0	32
113	Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leukemia and Lymphoma, 2010, 51, 1269-1277.	1.3	31
114	Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease. American Journal of Medicine, 1982, 72, 385-390.	1.5	30
115	Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2001, 19, 750-755.	1.6	29
116	Obatoclox Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>. Molecular Cancer Therapeutics, 2012, 11, 1122-1132.	4.1	29
117	Iodine-131 tositumomab (Bexxarâˆ®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkinâ€™s lymphoma. Expert Review of Anticancer Therapy, 2004, 4, 18-26.	2.4	27
118	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research, 2010, 34, 379-386.	0.8	26
119	Genetic polymorphisms in oxidative stressâ€œrelated genes are associated with outcomes following treatment for aggressive Bâ€œcell nonâ€œHodgkin lymphoma. American Journal of Hematology, 2014, 89, 639-645.	4.1	26
120	Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. American Journal of Medicine, 1981, 71, 967-972.	1.5	25
121	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. Clinical Cancer Research, 2010, 16, 2435-2442.	7.0	25
122	Effect of Adding Rituximab to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).. Blood, 2004, 104, 158-158.	1.4	25
123	Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals of Oncology, 1991, 2, 33-35.	1.2	23
124	Ovarian cancer: A solid tumor with evidence of normal cellular immune function but abnormal B cell function. American Journal of Medicine, 1979, 66, 621-624.	1.5	22
125	Treatment of aggressive non-hodgkin's lymphomas: Lessons from the past 10 years. Cancer, 1994, 74, 2657-2661.	4.1	22
126	The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Current Opinion in Oncology, 2006, 18, 417-424.	2.4	22

#	ARTICLE	IF	CITATIONS
127	Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial. <i>Anti-Cancer Drugs</i> , 2000, 11, 695-700.	1.4	21
128	Mantle Cell Lymphoma: At Last, Some Hope for Successful Innovative Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2005, 23, 657-658.	1.6	21
129	Phase I trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2016, 57, 635-643.	1.3	21
130	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq0 0 0 4.6 / Overlock 10 Tf	4.6	20
131	A Randomized Phase III Trial of ABVD Vs. Stanford V +/â'' Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010, 116, 415-415.	1.4	18
132	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. <i>Blood</i> , 2015, 125, 236-241.	1.4	17
133	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793;) Tj ETQq1 1 0 3 7 8 4 3 1 4 1 7 gBT / Over	1.4	17
134	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
135	Chemotherapy of Ovarian Cancer. <i>Surgical Clinics of North America</i> , 1978, 58, 143-150.	1.5	14
136	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 809-809.	1.4	13
137	Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517.. <i>Blood</i> , 2007, 110, 2574-2574.	1.4	13
138	Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A southwest oncology group study. <i>Hematological Oncology</i> , 1994, 12, 75-85.	1.7	11
139	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. <i>Blood</i> , 2007, 110, 348-348.	1.4	11
140	A SOUTHWEST ONCOLOGY GROUP PERSPECTIVE ON THE REVISED EUROPEAN-AMERICAN LYMPHOMA CLASSIFICATION. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 819-846.	2.2	10
141	The Role of Myeloablation for Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 574-576.	27.0	10
142	Autologous Bone Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma: Lessons Learned and Challenges Remaining. <i>Journal of the National Cancer Institute</i> , 2001, 93, 4-5.	6.3	9
143	Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 640-647.	2.0	9
144	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1934-1941.	1.3	9

#	ARTICLE	IF	CITATIONS
145	The PKC β Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.. Blood, 2005, 106, 1483-1483.	1.4	9
146	Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin's Lymphoma: Resolved Issues Versus Remaining Opportunity. Journal of Clinical Oncology, 2002, 20, 4411-4412.	1.6	7
147	Advanced Insights Into the Biology of Malignant Lymphomas. Journal of Clinical Oncology, 2011, 29, 1799-1800.	1.6	7
148	Diffuse Large B-Cell NHL. , 2006, 131, 121-140.		6
149	Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.. Blood, 2004, 104, 3263-3263.	1.4	6
150	Effect of Adding Ibrutinib (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG) Tj ETQq01040 rgBT (Overlock 1		
151	An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar $\text{\textcircled{R}}$) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911.. Blood, 2005, 106, 352-352.	1.4	5
152	Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood, 2013, 122, 4375-4375.	1.4	5
153	Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non-Hodgkin's lymphomas. Cancer, 1984, 54, 2936-2942.	4.1	4
154	Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leukemia and Lymphoma, 2013, 54, 2185-2189.	1.3	4
155	CHOP Therapy: Has Shorter-Course Therapy Had an Impact on Lymphomas?. Cancer Investigation, 1998, 16, 26-32.	1.3	3
156	Diffuse Large-Cell Lymphomas: A Review of Therapy. Clinical Lymphoma and Myeloma, 2001, 2, 155-163.	2.1	3
157	Treatment of Diffuse Large B-Cell Lymphomas. Seminars in Hematology, 2006, 43, 205-206.	3.4	3
158	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. Journal of Clinical Oncology, 2015, 33, 1221-1223.	1.6	3
159	Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. Journal of Cancer Survivorship, 2017, 11, 32-40.	2.9	3
160	Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. Blood, 2016, 128, 616-616.	1.4	3
161	A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma. Blood, 2020, 136, 24-25.	1.4	3
162	Is Observation Dead in Follicular Lymphoma? No, But the Apoptosis Pathway Has Been Activated. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 363-366.	4.9	2

#	ARTICLE	IF	CITATIONS
163	Venous Thromboembolic Events in Patients with Diffuse Large B cell Non-Hodgkin's Lymphoma.. Blood, 2004, 104, 4542-4542.	1.4	2
164	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. Blood, 2007, 110, 692-692.	1.4	2
165	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. Blood, 2007, 110, 2631-2631.	1.4	2
166	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2009, 27, e27-e28.	1.6	1
167	Reply to G. Keramida et al. Journal of Clinical Oncology, 2015, 33, 4121-4122.	1.6	1
168	Treatment of aggressive non-hodgkin's lymphomas: Lessons from the past 10 years. Cancer, 1994, 74, 2657-2661.	4.1	1
169	Central Nervous System (CNS) Relapse in Agressive Non-Hodgkin's Lymphoma; Does CNS Prophylaxis Work?.. Blood, 2007, 110, 520-520.	1.4	1
170	MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study. Blood, 2012, 120, 543-543.	1.4	1
171	Real-World Application of National Comprehensive Cancer Network (NCCN) Testing Guidelines in Diffuse Large B-Cell Lymphoma (DLBCL) Results in Underdiagnosis of Double-Hit Lymphoma. Blood, 2019, 134, 3426-3426.	1.4	1
172	Interferon Does Not Prolong Progression-Free Survival After ProMACE-MOPP. Journal of Clinical Oncology, 2000, 18, 3322-3322.	1.6	0
173	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. Blood, 2004, 104, 697-697.	1.4	0
174	The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF- κ B Inactivation, and DNA Damage... Blood, 2009, 114, 1688-1688.	1.4	0
175	Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016. Blood, 2019, 134, 2771-2771.	1.4	0